首页 > 最新文献

International Journal of Laboratory Hematology最新文献

英文 中文
Supplement Article 补充文章
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-11-24 DOI: 10.1111/ijlh.14396
{"title":"Supplement Article","authors":"","doi":"10.1111/ijlh.14396","DOIUrl":"https://doi.org/10.1111/ijlh.14396","url":null,"abstract":"","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"46 S2","pages":"3-121"},"PeriodicalIF":2.2,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14396","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142707990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increased Platelet Size and Elevated P2Y12 mRNA Expression Levels in Patients With Diabetes Mellitus 糖尿病患者血小板体积增大和 P2Y12 mRNA 表达水平升高
IF 3 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-09-17 DOI: 10.1111/ijlh.14372
Masako Nishikawa, Yutaka Nagura, Hitoshi Okazaki, Makoto Kurano, Yutaka Yatomi
{"title":"Increased Platelet Size and Elevated P2Y12 mRNA Expression Levels in Patients With Diabetes Mellitus","authors":"Masako Nishikawa, Yutaka Nagura, Hitoshi Okazaki, Makoto Kurano, Yutaka Yatomi","doi":"10.1111/ijlh.14372","DOIUrl":"https://doi.org/10.1111/ijlh.14372","url":null,"abstract":"","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"86 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deep Learning‐Based Blood Abnormalities Detection as a Tool for VEXAS Syndrome Screening 将基于深度学习的血液异常检测作为 VEXAS 综合征筛查工具
IF 3 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-09-14 DOI: 10.1111/ijlh.14368
Cédric De Almeida Braga, Maxence Bauvais, Pierre Sujobert, Maël Heiblig, Maxime Jullien, Baptiste Le Calvez, Camille Richard, Valentin Le Roc'h, Emmanuelle Rault, Olivier Hérault, Pierre Peterlin, Alice Garnier, Patrice Chevallier, Simon Bouzy, Yannick Le Bris, Antoine Néel, Julie Graveleau, Olivier Kosmider, Perrine Paul‐Gilloteaux, Nicolas Normand, Marion Eveillard
IntroductionVEXAS is a syndrome described in 2020, caused by mutations of the UBA1 gene, and displaying a large pleomorphic array of clinical and hematological features. Nevertheless, these criteria lack significance to discriminate VEXAS from other inflammatory conditions at the screening step. This work hence first focused on singling out dysplastic features indicative of the syndrome among peripheral blood (PB) polymorphonuclears (PMN). A deep learning algorithm is then proposed for automatic detection of these features.MethodsA multicentric dataset, comprising 9514 annotated PMN images was gathered, including UBA1 mutated VEXAS (n = 25), UBA1 wildtype myelodysplastic (n = 14), and UBA1 wildtype cytopenic patients (n = 25). Statistical analysis on a subset of patients was performed to screen for significant abnormalities. Detection of these features on PB was then automated with a convolutional neural network (CNN) for multilabel classification.ResultsSignificant differences were observed in the proportions of PMNs with pseudo‐Pelger, nuclear spikes, vacuoles, and hypogranularity between patients with VEXAS and both cytopenic and myelodysplastic controls.Automatic detection of these abnormalities yielded AUCs in the range [0.85–0.97] and a F1‐score of 0.70 on the test set. A VEXAS screening score was proposed, leveraging the model outputs and predicting the UBA1 mutational status with 0.82 sensitivity and 0.71 specificity on the test patients.ConclusionThis study suggests that computer‐assisted analysis of PB smears, focusing on suspected VEXAS cases, can provide valuable insights for determining which patients should undergo molecular testing. The presented deep learning approach can help hematologists direct their suspicions before initiating further analyses.
导言VEXAS是2020年描述的一种综合征,由UBA1基因突变引起,表现出大量多形性的临床和血液学特征。然而,在筛查阶段,这些标准对于区分 VEXAS 和其他炎症缺乏意义。因此,这项工作首先侧重于在外周血(PB)多形核细胞(PMN)中挑出表明该综合征的发育不良特征。方法收集了一个多中心数据集,包括 9514 张注释 PMN 图像,其中包括 UBA1 突变 VEXAS(n = 25)、UBA1 野生型骨髓增生异常(n = 14)和 UBA1 野生型细胞减少患者(n = 25)。对部分患者进行了统计分析,以筛查重大异常。结果发现,VEXAS 患者与细胞增生症和骨髓增生异常对照组之间,具有假性佩尔格、核尖峰、空泡和颗粒减少的 PMN 的比例存在显著差异。这项研究表明,计算机辅助分析 PB 涂片(侧重于疑似 VEXAS 病例)可为确定哪些患者应接受分子检测提供有价值的见解。所介绍的深度学习方法可帮助血液学专家在开始进一步分析前引导他们的怀疑。
{"title":"Deep Learning‐Based Blood Abnormalities Detection as a Tool for VEXAS Syndrome Screening","authors":"Cédric De Almeida Braga, Maxence Bauvais, Pierre Sujobert, Maël Heiblig, Maxime Jullien, Baptiste Le Calvez, Camille Richard, Valentin Le Roc'h, Emmanuelle Rault, Olivier Hérault, Pierre Peterlin, Alice Garnier, Patrice Chevallier, Simon Bouzy, Yannick Le Bris, Antoine Néel, Julie Graveleau, Olivier Kosmider, Perrine Paul‐Gilloteaux, Nicolas Normand, Marion Eveillard","doi":"10.1111/ijlh.14368","DOIUrl":"https://doi.org/10.1111/ijlh.14368","url":null,"abstract":"IntroductionVEXAS is a syndrome described in 2020, caused by mutations of the <jats:italic>UBA1</jats:italic> gene, and displaying a large pleomorphic array of clinical and hematological features. Nevertheless, these criteria lack significance to discriminate VEXAS from other inflammatory conditions at the screening step. This work hence first focused on singling out dysplastic features indicative of the syndrome among peripheral blood (PB) polymorphonuclears (PMN). A deep learning algorithm is then proposed for automatic detection of these features.MethodsA multicentric dataset, comprising 9514 annotated PMN images was gathered, including <jats:italic>UBA1</jats:italic> mutated VEXAS (<jats:italic>n</jats:italic> = 25), <jats:italic>UBA1</jats:italic> wildtype myelodysplastic (<jats:italic>n</jats:italic> = 14), and <jats:italic>UBA1</jats:italic> wildtype cytopenic patients (<jats:italic>n</jats:italic> = 25). Statistical analysis on a subset of patients was performed to screen for significant abnormalities. Detection of these features on PB was then automated with a convolutional neural network (CNN) for multilabel classification.ResultsSignificant differences were observed in the proportions of PMNs with pseudo‐Pelger, nuclear spikes, vacuoles, and hypogranularity between patients with VEXAS and both cytopenic and myelodysplastic controls.Automatic detection of these abnormalities yielded AUCs in the range [0.85–0.97] and a F1‐score of 0.70 on the test set. A VEXAS screening score was proposed, leveraging the model outputs and predicting the <jats:italic>UBA1</jats:italic> mutational status with 0.82 sensitivity and 0.71 specificity on the test patients.ConclusionThis study suggests that computer‐assisted analysis of PB smears, focusing on suspected VEXAS cases, can provide valuable insights for determining which patients should undergo molecular testing. The presented deep learning approach can help hematologists direct their suspicions before initiating further analyses.","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"25 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab‐Treated Patients With Multiple Myeloma 干扰素调节因子 4:达拉单抗治疗的多发性骨髓瘤患者血浆细胞的替代标记物
IF 3 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-09-13 DOI: 10.1111/ijlh.14366
Suwen Yang, Qianwen Hu, Xiaofen Wang, Sai Qiao, Chao Qi, Hong Jin, Yuhong Zhong
IntroductionAnti‐CD38 therapeutic modalities (e.g., daratumumab) can impede classical CD38 and CD138 gating use for plasma cell (PC) detection in multiple myeloma (MM) patients with minimal residual disease (MRD). We assessed the applicability of CD229, CD269, and interferon regulatory factor (IRF‐4) for PC detection in MM MRD patients.MethodsBone marrow samples were collected from patients with MM. Through multiparameter flow cytometry, we evaluated the suitability of CD229, CD269, and IRF‐4 for distinguishing PCs from other hematopoietic cells and compared their expression pattern on normal PCs (nPCs) and aberrant PCs (aPCs). We also assessed IRF‐4 expression stability after sample storage under different conditions. A 10‐color MRD antibody panel was used to determine whether IRF‐4 is an alternative primary PC‐gating marker for MM MRD assessment.ResultsIRF‐4 was expressed specifically on all PCs; its mean fluorescence intensity (MFI) was highest on PCs among all hematopoietic cells. This MFI did not decrease even after sample storage at 4°C or 25°C for 72 h. In all 42 MRD assessment samples, except for samples (n = 10) with no PCs, the use of IRF‐4 enabled accurate nPC (n = 12), aPC (n = 13), and nPC + aPC (n = 7) identification. Even samples from daratumumab‐treated patients had high IRF‐4 MFI, with no difference between pre‐treatment and post‐treatment (n = 7; p = 0.610).ConclusionsIRF‐4 demonstrates high MFI on PCs, and it is not expressed on other leukocytes. In MM patients with MRD, daratumumab treatment does not affect IRF‐4 expression. IRF‐4 is a promising marker for PC identification in MRD assessment of MM patients undergoing anti‐CD38 therapy.
引言抗 CD38 治疗方法(如达拉单抗)可能会阻碍对患有极小残留病(MRD)的多发性骨髓瘤(MM)患者进行经典的 CD38 和 CD138 门检测浆细胞(PC)。我们评估了CD229、CD269和干扰素调节因子(IRF-4)在MM MRD患者PC检测中的适用性。通过多参数流式细胞术,我们评估了 CD229、CD269 和 IRF-4 在区分 PC 与其他造血细胞方面的适用性,并比较了它们在正常 PC(nPC)和异常 PC(aPC)上的表达模式。我们还评估了不同条件下样本储存后 IRF-4 表达的稳定性。结果IRF-4在所有PC上都有特异性表达;在所有造血细胞中,PC上的平均荧光强度(MFI)最高。在所有 42 份 MRD 评估样本中,除了没有 PC 的样本(n = 10)外,IRF-4 都能准确鉴定 nPC(n = 12)、aPC(n = 13)和 nPC + aPC(n = 7)。结论IRF-4在PC上的MFI很高,在其他白细胞上没有表达。在有MRD的MM患者中,达拉土单抗治疗不会影响IRF-4的表达。在对接受抗CD38治疗的MM患者进行MRD评估时,IRF-4是一种很有希望的PC鉴定标志物。
{"title":"Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab‐Treated Patients With Multiple Myeloma","authors":"Suwen Yang, Qianwen Hu, Xiaofen Wang, Sai Qiao, Chao Qi, Hong Jin, Yuhong Zhong","doi":"10.1111/ijlh.14366","DOIUrl":"https://doi.org/10.1111/ijlh.14366","url":null,"abstract":"IntroductionAnti‐CD38 therapeutic modalities (e.g., daratumumab) can impede classical CD38 and CD138 gating use for plasma cell (PC) detection in multiple myeloma (MM) patients with minimal residual disease (MRD). We assessed the applicability of CD229, CD269, and interferon regulatory factor (IRF‐4) for PC detection in MM MRD patients.MethodsBone marrow samples were collected from patients with MM. Through multiparameter flow cytometry, we evaluated the suitability of CD229, CD269, and IRF‐4 for distinguishing PCs from other hematopoietic cells and compared their expression pattern on normal PCs (nPCs) and aberrant PCs (aPCs). We also assessed IRF‐4 expression stability after sample storage under different conditions. A 10‐color MRD antibody panel was used to determine whether IRF‐4 is an alternative primary PC‐gating marker for MM MRD assessment.ResultsIRF‐4 was expressed specifically on all PCs; its mean fluorescence intensity (MFI) was highest on PCs among all hematopoietic cells. This MFI did not decrease even after sample storage at 4°C or 25°C for 72 h. In all 42 MRD assessment samples, except for samples (<jats:italic>n</jats:italic> = 10) with no PCs, the use of IRF‐4 enabled accurate nPC (<jats:italic>n</jats:italic> = 12), aPC (<jats:italic>n</jats:italic> = 13), and nPC + aPC (<jats:italic>n</jats:italic> = 7) identification. Even samples from daratumumab‐treated patients had high IRF‐4 MFI, with no difference between pre‐treatment and post‐treatment (<jats:italic>n</jats:italic> = 7; <jats:italic>p</jats:italic> = 0.610).ConclusionsIRF‐4 demonstrates high MFI on PCs, and it is not expressed on other leukocytes. In MM patients with MRD, daratumumab treatment does not affect IRF‐4 expression. IRF‐4 is a promising marker for PC identification in MRD assessment of MM patients undergoing anti‐CD38 therapy.","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"35 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel TNFRSF13B frameshift variant in one family with lymphoid neoplasms 一个淋巴肿瘤家族中的新型 TNFRSF13B 框移变体
IF 3 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-09-13 DOI: 10.1111/ijlh.14359
Jing Li, Huici Gu, Shu Zhang, Xiaobo Mao, Junyan Zou, Xiaopeng Zhang, Guangxin Peng
{"title":"A novel TNFRSF13B frameshift variant in one family with lymphoid neoplasms","authors":"Jing Li, Huici Gu, Shu Zhang, Xiaobo Mao, Junyan Zou, Xiaopeng Zhang, Guangxin Peng","doi":"10.1111/ijlh.14359","DOIUrl":"https://doi.org/10.1111/ijlh.14359","url":null,"abstract":"","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"102 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frozen/Thawed Samples Can Replace Fresh Samples for Assignment of ISI to Secondary Thromboplastin Standards for Multiple Reagent/Instrument Combinations: Data to Support Possible Revision of WHO Guidelines 冷冻/解冻样本可替代新鲜样本,用于为多个试剂盒/仪器组合的次级凝血酶原标准分配 ISI:支持可能修订世界卫生组织指南的数据
IF 3 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-09-13 DOI: 10.1111/ijlh.14369
Matthew Kitchen, Michelle Bryant, Paula Brown, Anita Woolley, Steve Kitchen
BackgroundCalibration of thromboplastins is required for accurate calculation of the international normalised ratio (INR). Accurate INR results are required for optimal dosing of vitamin K antagonists. Decreases in vitamin K antagonist usage have made the recruitment of sample sets for international sensitivity index (ISI) calibrations more difficult. A possible solution to this would be to allow the use of frozen–thawed samples in place of fresh plasmas in the calibration of secondary standards.ObjectivesWe investigated the effect of freezing and thawing samples before usage in ISI calibrations of secondary standards.MethodsMultiple reagent/instruments were tested to identify the degree of difference between a fresh sample ISI calibration and one performed on frozen–thawed samples. Where possible, the two ISI calibrations were performed on the same sample set. Alternatively, a separate set of samples from different patients was used.ResultsThe difference in ISI values was <3% for those datasets where the same samples were used, and <6% for those datasets where two sample sets were used. Additionally, other parameters required for a valid ISI calibration showed only minor differences—some calibrations showed fewer outliers in the frozen–thawed datasets. Mean normal prothrombin time for the international reference thromboplastins was <3.5% different across four different calibrations (two for rabbit thromboplastin and two for recombinant human thromboplastin).ConclusionsThis modification to the WHO guidelines would facilitate the recruitment of test plasmas in advance of calibration solving the problem of requiring availability of fresh patient samples with a range of INRs in a 5‐h window.Trial Registration: Not a part of any clinical trial.
背景要准确计算国际正常化比率(INR),需要校准凝血酶。准确的 INR 结果是维生素 K 拮抗剂最佳剂量的必要条件。由于维生素 K 拮抗剂用量的减少,为国际灵敏度指数(ISI)校准招募样本集变得更加困难。我们研究了在二级标准的 ISI 校准中使用前冷冻和解冻样本的影响。方法测试了多个试剂盒/仪器,以确定新鲜样本 ISI 校准与冷冻解冻样本 ISI 校准之间的差异程度。在可能的情况下,两种 ISI 校准在同一组样品上进行。结果使用相同样本的数据集的 ISI 值差异为 <3%,使用两套样本的数据集的 ISI 值差异为 <6%。此外,有效的 ISI 校准所需的其他参数也只显示出微小差异--一些校准结果显示,冷冻-解冻数据集中的异常值较少。国际参考凝血酶原的平均正常凝血酶原时间在四次不同的校准(两次为兔凝血酶原,两次为重组人凝血酶原)中相差 3.5%。结论对世界卫生组织指南的这一修改将有助于在校准前招募测试血浆,解决了需要在 5 小时窗口期内提供具有一系列 INR 的新鲜患者样本的问题:未参加任何临床试验。
{"title":"Frozen/Thawed Samples Can Replace Fresh Samples for Assignment of ISI to Secondary Thromboplastin Standards for Multiple Reagent/Instrument Combinations: Data to Support Possible Revision of WHO Guidelines","authors":"Matthew Kitchen, Michelle Bryant, Paula Brown, Anita Woolley, Steve Kitchen","doi":"10.1111/ijlh.14369","DOIUrl":"https://doi.org/10.1111/ijlh.14369","url":null,"abstract":"BackgroundCalibration of thromboplastins is required for accurate calculation of the international normalised ratio (INR). Accurate INR results are required for optimal dosing of vitamin K antagonists. Decreases in vitamin K antagonist usage have made the recruitment of sample sets for international sensitivity index (ISI) calibrations more difficult. A possible solution to this would be to allow the use of frozen–thawed samples in place of fresh plasmas in the calibration of secondary standards.ObjectivesWe investigated the effect of freezing and thawing samples before usage in ISI calibrations of secondary standards.MethodsMultiple reagent/instruments were tested to identify the degree of difference between a fresh sample ISI calibration and one performed on frozen–thawed samples. Where possible, the two ISI calibrations were performed on the same sample set. Alternatively, a separate set of samples from different patients was used.ResultsThe difference in ISI values was &lt;3% for those datasets where the same samples were used, and &lt;6% for those datasets where two sample sets were used. Additionally, other parameters required for a valid ISI calibration showed only minor differences—some calibrations showed fewer outliers in the frozen–thawed datasets. Mean normal prothrombin time for the international reference thromboplastins was &lt;3.5% different across four different calibrations (two for rabbit thromboplastin and two for recombinant human thromboplastin).ConclusionsThis modification to the WHO guidelines would facilitate the recruitment of test plasmas in advance of calibration solving the problem of requiring availability of fresh patient samples with a range of INRs in a 5‐h window.Trial Registration: Not a part of any clinical trial.","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"207 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A new digital droplet PCR method for looking at epigenetics in diffuse large B‐cell lymphomas: The role of BMI1, EZH2, and USP22 genes 研究弥漫大 B 细胞淋巴瘤表观遗传学的新型数字液滴 PCR 方法:BMI1、EZH2 和 USP22 基因的作用
IF 3 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-09-10 DOI: 10.1111/ijlh.14363
Alessio Lusci Gemignani, Robel Papotti, Riccardo Bomben, Valter Gattei, Samantha Pozzi, Valentina Donati, Stefania Bettelli, Elisa Forti, Giovanna Mansueto, Arianna Di Napoli, Maria Christina Cox, Leonardo Flenghi, Pietro Rossi, Guido Volpe, Dimitri Dardanis, Clara Bono, Francesca Guerrini, Riccardo Morganti, Stefano Sacchi, Sara Galimberti
IntroductionEpigenetics has been shown to be relevant in oncology: BMI1 overexpression has been reported in leukemias, EZH2 mutations have been found in follicular lymphoma, and USP22 seems to stabilize BMI1 protein. In this study, we measured the expression of BMI1, EZH2, and USP22 in lymph nodes from 56 diffuse large B‐cell lymphoma (DLBCL) patients.MethodsA new multiplex digital droplet PCR (ddPCR) has been set up to measure the expression of 4 genes (BMI1, EZH2, USP22, and GAPDH) in the same reaction on RNA extracted from paraffin‐embedded tissues.ResultsThe specificity of ddPCR was confirmed by a 100% alignment on the BLAST platform and its repeatability demonstrated by duplicates. A strict correlation between expression of BMI1 and EZH2 and BMI1 and USP22 has been found, and high expression of these genes was correlated with extra‐nodal lymphomas. Progression‐free survival (PFS) and overall survival (OS) were conditioned by IPI, bone marrow infiltration, and the complete response achievement. High levels of BMI1 and USP22 did not condition the response to therapy, but impaired the PFS, especially for patients defined at “high risk” based on the cell of origin (no germinal center [GCB]), high BCL2 expression, and IPI 3‐5. In this subgroup, the probability of relapse/progression was twice higher than that of patients carrying low BMI1 and USP22 levels.ConclusionHigh expression of BMI1 and of USP22 might be a poor prognostic factor in DLBCL, and might represent the target for novel inhibitors.
导言表观遗传学已被证明与肿瘤学有关:据报道,BMI1在白血病中过表达,EZH2突变在滤泡性淋巴瘤中被发现,而USP22似乎能稳定BMI1蛋白。本研究测定了 56 例弥漫大 B 细胞淋巴瘤(DLBCL)患者淋巴结中 BMI1、EZH2 和 USP22 的表达。方法 建立了一种新的多重数字液滴 PCR(ddPCR),在同一反应中测量从石蜡包埋组织中提取的 RNA 中 4 个基因(BMI1、EZH2、USP22 和 GAPDH)的表达。结果发现,BMI1 和 EZH2 以及 BMI1 和 USP22 的表达之间存在严格的相关性,这些基因的高表达与结外淋巴瘤相关。无进展生存期(PFS)和总生存期(OS)受 IPI、骨髓浸润和完全反应成就的影响。高水平的BMI1和USP22不会影响治疗反应,但会影响无进展生存期,尤其是根据起源细胞(无生殖中心[GCB])、BCL2高表达和IPI 3-5定义的 "高危 "患者。结论BMI1和USP22的高表达可能是DLBCL的不良预后因素,可能是新型抑制剂的靶点。
{"title":"A new digital droplet PCR method for looking at epigenetics in diffuse large B‐cell lymphomas: The role of BMI1, EZH2, and USP22 genes","authors":"Alessio Lusci Gemignani, Robel Papotti, Riccardo Bomben, Valter Gattei, Samantha Pozzi, Valentina Donati, Stefania Bettelli, Elisa Forti, Giovanna Mansueto, Arianna Di Napoli, Maria Christina Cox, Leonardo Flenghi, Pietro Rossi, Guido Volpe, Dimitri Dardanis, Clara Bono, Francesca Guerrini, Riccardo Morganti, Stefano Sacchi, Sara Galimberti","doi":"10.1111/ijlh.14363","DOIUrl":"https://doi.org/10.1111/ijlh.14363","url":null,"abstract":"IntroductionEpigenetics has been shown to be relevant in oncology: <jats:italic>BMI1</jats:italic> overexpression has been reported in leukemias, <jats:italic>EZH2</jats:italic> mutations have been found in follicular lymphoma, and <jats:italic>USP22</jats:italic> seems to stabilize BMI1 protein. In this study, we measured the expression of <jats:italic>BMI1, EZH2</jats:italic>, and <jats:italic>USP22</jats:italic> in lymph nodes from 56 diffuse large B‐cell lymphoma (DLBCL) patients.MethodsA new multiplex digital droplet PCR (ddPCR) has been set up to measure the expression of 4 genes (<jats:italic>BMI1, EZH2, USP22</jats:italic>, and <jats:italic>GAPDH</jats:italic>) in the same reaction on RNA extracted from paraffin‐embedded tissues.ResultsThe specificity of ddPCR was confirmed by a 100% alignment on the BLAST platform and its repeatability demonstrated by duplicates. A strict correlation between expression of <jats:italic>BMI1</jats:italic> and <jats:italic>EZH2</jats:italic> and <jats:italic>BMI1</jats:italic> and <jats:italic>USP22</jats:italic> has been found, and high expression of these genes was correlated with extra‐nodal lymphomas. Progression‐free survival (PFS) and overall survival (OS) were conditioned by IPI, bone marrow infiltration, and the complete response achievement. High levels of <jats:italic>BMI1</jats:italic> and <jats:italic>USP22</jats:italic> did not condition the response to therapy, but impaired the PFS, especially for patients defined at “high risk” based on the cell of origin (no germinal center [GCB]), high BCL2 expression, and IPI 3‐5. In this subgroup, the probability of relapse/progression was twice higher than that of patients carrying low <jats:italic>BMI1</jats:italic> and <jats:italic>USP22</jats:italic> levels.ConclusionHigh expression of <jats:italic>BMI1</jats:italic> and of <jats:italic>USP22</jats:italic> might be a poor prognostic factor in DLBCL, and might represent the target for novel inhibitors.","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"4 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142218227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brief communication: Heparin-calibrated chromogenic anti-Xa assay for the detection of threshold-levels of direct oral anticoagulants 简要通讯:用于检测直接口服抗凝剂阈值水平的肝素校准显色抗 Xa 试验。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-08-23 DOI: 10.1111/ijlh.14357
Delphine De Smet, Dimitri Hemelsoet, Veerle De Herdt, Pieter M. De Kesel, Katrien M. J. Devreese
{"title":"Brief communication: Heparin-calibrated chromogenic anti-Xa assay for the detection of threshold-levels of direct oral anticoagulants","authors":"Delphine De Smet,&nbsp;Dimitri Hemelsoet,&nbsp;Veerle De Herdt,&nbsp;Pieter M. De Kesel,&nbsp;Katrien M. J. Devreese","doi":"10.1111/ijlh.14357","DOIUrl":"10.1111/ijlh.14357","url":null,"abstract":"","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"46 6","pages":"1136-1139"},"PeriodicalIF":2.2,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142038090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An automated method for thrombocyte counting in capillary microsamples 毛细管微型样本中血小板计数的自动方法。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-08-14 DOI: 10.1111/ijlh.14354
Caroline Vasard Boesen, Vibeke Staun Christensen, Klaus Rosenkilde Jensen, Anja Reinert Hansen, Claus Vinter Bødker Hviid

Introduction

We aimed to develop an automated, low-volume method for thrombocyte counting in capillary blood using the Sysmex predilution (PD) mode.

Methods

Microsamples were prepared by resuspension of 50 μL blood in 300 μL DCL CellPack. Thrombocyte counting was done in the impedance (PLT-I) and fluorescence (PLT-F) channels. The imprecision and bias was evaluated in >394 microsamples from adult blood. Preanalytical factors (skin-piercing, storage, and transportation in our pneumatic tube system) was assessed, and studies on pediatric microsamples were made for comparison. The improvement in analytical quality and turnaround time was examined.

Results

For PLT-F, the imprecision was 1.1%–3.7%, and the bias was 10.1% (95% CI: 8.8–11.3). After skin-piercing, the bias was 8.1% (95% CI: 5.6–10.6) and the imprecision 1.9% (95% CI: 1.3–2.5). Thrombocyte counts kept stable after 4 h at room temperature (94.8% [95% CI: 93.2–96.4]) and after pneumatic tube transportation [6.7% (95% CI: 4.8–8.6)]. The bias of the PD mode for pediatric microsamples was 13.0% (95% CI: −8.4–34.4) in the PLT-F channel. The automated method had a considerably lower imprecision than the existing manual thrombocyte counting method and reduced turnaround times.

Conclusion

The automated microsample method offers a low-volume alternative for measurement of thrombocytes. The method appears useful also in pediatric samples.

简介:我们的目的是利用 Sysmex 预稀释(PD)模式开发一种自动、低容量的毛细管血液血小板计数方法:我们的目标是利用 Sysmex 预稀释(PD)模式开发一种自动、低容量的毛细管血液血小板计数方法:方法:用 300 μL DCL CellPack 重悬 50 μL 血液制备微量样本。在阻抗(PLT-I)和荧光(PLT-F)通道中进行血小板计数。在大于 394 个成人血液微量样本中对不精确度和偏差进行了评估。对分析前因素(皮肤穿刺、储存和气管系统运输)进行了评估,并对儿科微量样本进行了比较研究。对分析质量和周转时间的改善进行了研究:对于 PLT-F,不精确度为 1.1%-3.7%,偏差为 10.1%(95% CI:8.8-11.3)。皮肤穿刺后,偏差为 8.1%(95% CI:5.6-10.6),不精确度为 1.9%(95% CI:1.3-2.5)。室温下 4 小时后(94.8% [95% CI:93.2-96.4])和气管运输后[6.7% (95% CI:4.8-8.6)],血小板计数保持稳定。在 PLT-F 通道中,儿科微量样本的 PD 模式偏差为 13.0%(95% CI:-8.4-34.4)。与现有的手动血小板计数方法相比,自动方法的不精确度要低得多,而且减少了周转时间:结论:自动微样本方法为测量血小板提供了一种低容量的替代方法。结论:自动微量样本法为测量血小板提供了一种低容量的替代方法,该方法似乎也适用于儿科样本。
{"title":"An automated method for thrombocyte counting in capillary microsamples","authors":"Caroline Vasard Boesen,&nbsp;Vibeke Staun Christensen,&nbsp;Klaus Rosenkilde Jensen,&nbsp;Anja Reinert Hansen,&nbsp;Claus Vinter Bødker Hviid","doi":"10.1111/ijlh.14354","DOIUrl":"10.1111/ijlh.14354","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>We aimed to develop an automated, low-volume method for thrombocyte counting in capillary blood using the Sysmex predilution (PD) mode.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Microsamples were prepared by resuspension of 50 μL blood in 300 μL DCL CellPack. Thrombocyte counting was done in the impedance (PLT-I) and fluorescence (PLT-F) channels. The imprecision and bias was evaluated in &gt;394 microsamples from adult blood. Preanalytical factors (skin-piercing, storage, and transportation in our pneumatic tube system) was assessed, and studies on pediatric microsamples were made for comparison. The improvement in analytical quality and turnaround time was examined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>For PLT-F, the imprecision was 1.1%–3.7%, and the bias was 10.1% (95% CI: 8.8–11.3). After skin-piercing, the bias was 8.1% (95% CI: 5.6–10.6) and the imprecision 1.9% (95% CI: 1.3–2.5). Thrombocyte counts kept stable after 4 h at room temperature (94.8% [95% CI: 93.2–96.4]) and after pneumatic tube transportation [6.7% (95% CI: 4.8–8.6)]. The bias of the PD mode for pediatric microsamples was 13.0% (95% CI: −8.4–34.4) in the PLT-F channel. The automated method had a considerably lower imprecision than the existing manual thrombocyte counting method and reduced turnaround times.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The automated microsample method offers a low-volume alternative for measurement of thrombocytes. The method appears useful also in pediatric samples.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"46 6","pages":"1044-1051"},"PeriodicalIF":2.2,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14354","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141977464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Establishing reflex test rules for platelet fluorescent counting method using machine learning models on Sysmex XN-series hematology analyzer 在 Sysmex XN 系列血液分析仪上使用机器学习模型建立血小板荧光计数法的反射测试规则。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2024-08-05 DOI: 10.1111/ijlh.14353
Zhengyu Zhou, Mengqiao Guo, Kang Wu, Zhanyi Yue

Introduction

The platelet fluorescent counting (PLT-F) method is utilized as a reflex test method following the initial test of the platelet impedance counting (PLT-I) method in clinical practice on the Sysmex XN-series automated hematology analyzer. Our aim is to establish reflex test rules for the PLT-F method by combining multiple parameters provided by the “CBC + DIFF” mode of the Sysmex XN-series automated hematology analyzer.

Methods

We tested 120 samples to evaluate the baseline bias between the PLT-F and PLT-I methods. Then, we selected 1256 samples to establish and test reflex test rules using seven machine learning models (decision Tree, random forest, neural network, logistic regression, k-nearest neighbor, support vector machine, and Naive Bayes). The training set and test set were divided at a ratio of 7:3. We evaluated the performance of machine learning models on the test set using various metrics to select the most valuable model.

Results

The PLT-F method exhibited a high degree of correlation with the PLT-I method (r = 0.998). The random forest model emerged as the most valuable, boasting an accuracy of 0.893, an area under the curve of 0.954, an F1 score of 0.771, a recall of 0.719, a precision of 0.831, and a specificity of 0.950. The most important variable in the random forest model was mean cell volume, weighted at 15.09%.

Conclusion

The random forest model, which demonstrated high efficiency in our study, can be used to establish PLT reflex test rules based on the PLT-F method for the Sysmex XN-series automated hematology analyzer.

简介血小板荧光计数法(PLT-F)是在 Sysmex XN 系列全自动血液分析仪上对血小板阻抗计数法(PLT-I)进行初步测试后,在临床实践中作为一种反射测试方法使用的。我们的目的是结合 Sysmex XN 系列自动血液分析仪 "CBC + DIFF "模式提供的多个参数,为 PLT-F 方法建立反射测试规则:我们测试了 120 份样本,以评估 PLT-F 和 PLT-I 方法之间的基线偏差。然后,我们选择了 1256 个样本,使用七种机器学习模型(决策树、随机森林、神经网络、逻辑回归、k-近邻、支持向量机和 Naive Bayes)建立并测试反射测试规则。训练集和测试集的比例为 7:3。我们使用各种指标评估了机器学习模型在测试集上的表现,以选出最有价值的模型:结果:PLT-F 方法与 PLT-I 方法具有高度相关性(r = 0.998)。随机森林模型是最有价值的模型,其准确率为 0.893,曲线下面积为 0.954,F1 分数为 0.771,召回率为 0.719,精确度为 0.831,特异性为 0.950。随机森林模型中最重要的变量是平均细胞体积,权重为 15.09%:随机森林模型在我们的研究中表现出很高的效率,可用于为 Sysmex XN 系列全自动血液分析仪建立基于 PLT-F 方法的 PLT 反射检验规则。
{"title":"Establishing reflex test rules for platelet fluorescent counting method using machine learning models on Sysmex XN-series hematology analyzer","authors":"Zhengyu Zhou,&nbsp;Mengqiao Guo,&nbsp;Kang Wu,&nbsp;Zhanyi Yue","doi":"10.1111/ijlh.14353","DOIUrl":"10.1111/ijlh.14353","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The platelet fluorescent counting (PLT-F) method is utilized as a reflex test method following the initial test of the platelet impedance counting (PLT-I) method in clinical practice on the Sysmex XN-series automated hematology analyzer. Our aim is to establish reflex test rules for the PLT-F method by combining multiple parameters provided by the “CBC + DIFF” mode of the Sysmex XN-series automated hematology analyzer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We tested 120 samples to evaluate the baseline bias between the PLT-F and PLT-I methods. Then, we selected 1256 samples to establish and test reflex test rules using seven machine learning models (decision Tree, random forest, neural network, logistic regression, k-nearest neighbor, support vector machine, and Naive Bayes). The training set and test set were divided at a ratio of 7:3. We evaluated the performance of machine learning models on the test set using various metrics to select the most valuable model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The PLT-F method exhibited a high degree of correlation with the PLT-I method (r = 0.998). The random forest model emerged as the most valuable, boasting an accuracy of 0.893, an area under the curve of 0.954, an F1 score of 0.771, a recall of 0.719, a precision of 0.831, and a specificity of 0.950. The most important variable in the random forest model was mean cell volume, weighted at 15.09%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The random forest model, which demonstrated high efficiency in our study, can be used to establish PLT reflex test rules based on the PLT-F method for the Sysmex XN-series automated hematology analyzer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"46 6","pages":"1036-1043"},"PeriodicalIF":2.2,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141891345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Laboratory Hematology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1